Methylene blue: Potential use of an antique molecule in vasoplegic syndrome during cardiac surgery

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 12, 2011, Pages 1519-1525

  Lenglet, Sébastien ^a   MacH, Franois ^a   Montecucco, Fabrizio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

cardiac surgery; cardiopulmonary bypass; guanylate cyclase; methylene blue; nitric oxide synthase; vasoplegia

Indexed keywords

CYCLIC GMP; METHYLENE BLUE; NITRIC OXIDE; PLACEBO;

ANAPHYLACTIC SHOCK; ARTICLE; CARDIOPULMONARY BYPASS; CORONARY ARTERY CONSTRICTION; DRUG HYPERSENSITIVITY; DYSPNEA; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART OUTPUT; HEART SURGERY; HUMAN; HYPERTENSION; HYPOTENSION; LUNG VASCULAR RESISTANCE; NAUSEA AND VOMITING; RECOMMENDED DRUG DOSE; SIDE EFFECT; THORAX PAIN; VASOPLEGIA;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; INTRAOPERATIVE COMPLICATIONS; METHYLENE BLUE; NITRIC OXIDE SYNTHASE; POSTOPERATIVE COMPLICATIONS; SALVAGE THERAPY; VASOPLEGIA;

EID: 82755174026     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.160     Document Type: Article

References (55)

1. Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop. Med. Int. Health 10(6), 501-511 (2005). (Pubitemid 40806655)
2. Harvey BH, Duvenhage I, Viljoen F et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem. Pharmacol. 80(10), 1580-1591 (2010).
3. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you - methylene blue Neurobiol. Aging 32(12), 2325.e7-e16 (2011).
4. Stawicki SP, Sims C, Sarani B, Grossman MD, Gracias VH. Methylene blue and vasoplegia: who, when, and how? Mini Rev. Med. Chem. 8(5), 472-490 (2008).
5. Shanmugan G. Vasoplegic syndrome - the role of methylene blue. Eur. J. Cardiothorac. Surg. 28(5), 705-710 (2005).
6. Peter C, Hongwan D, Kpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 56(3), 247-250 (2000). (Pubitemid 30456685)
7. Ozal E, Kuralay E, Yildirim V et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann. Thorac. Surg. 79(5), 1615-1619 (2005). (Pubitemid 40614576)
8. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann. Emerg. Med. 30(2), 240 (1997).
9. Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J. Thorac. Cardiovasc. Surg. 119(3), 195-196 (2000).
10. Almeida JA, Riordan SM, Liu J et al. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur. J. Gastroenterol. Hepatol. 19(4), 341-346 (2007). (Pubitemid 46412078)
11. Clifton J, Leikin J. Methylene blue. Am. J. Ther. 10(4), 289-291 (2003).
12. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J. Psychopharmacol. 24(10), 1433-1438 (2010).
13. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br. J. Pharmacol. 152(6), 946-951 (2007). (Pubitemid 350100489)
14. Oz M, Isaev D, Lorke DE, Hasan M, Petroianu G, Shippenberg TS. Methylene blue inhibits serotonin transporter function. Br. J. Pharmacol. doi:10.1111/j.1476-5381.2011.01462.x (2011) (Epub ahead of print).
15. Jangjoo A, Forghani MN, Mehrabibahar M, Sadeghi R. Anaphylaxis reaction of a breast cancer patient to methylene blue during breast surgery with sentinel node mapping. Acta Oncol. 49(6), 877-878 (2010).
16. Dewachter P, Castro S, Nicaise-Roland P et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br. J. Anaesth. 106(5), 687-689 (2011).
17. Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 51(1), 125-128 (2011).
18. Telgenkamp B, Japink D, van Haaren E. Cardiac arrest after patent blue v injection for sentinel lymph node biopsy in breast cancer. Breast Care 5(6), 411-413 (2010).
19. Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res. A Clin. Mol. Teratol. 67(2), 133-140 (2003). (Pubitemid 38222006)
20. Ozal E, Kuralay E, Yildirim V et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann. Thorac. Surg. 79(5), 1615-1619 (2005). (Pubitemid 40614576)
21. Levin RL, Degrange MA, Bruno GF et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann. Thorac. Surg. 77(2), 496-499 (2004). (Pubitemid 38186498)
22. Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 120(17), 1664-1671 (2009).
23. Argenziano M, Chen JM, Choudhri AF et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J. Thorac. Cardiovasc. Surg. 116(6), 973-980 (1998). (Pubitemid 28553541)
24. Sun X, Zhang L, Hill PC et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur. J. Cardiothorac. Surg. 34(4), 820-825 (2008).
25. Brasil LA, Gomes WJ, Salomão R, Buffolo E. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann. Thorac. Surg. 66(1), 56-59 (1998). (Pubitemid 28389230)
26. Aydin NB, Gercekoglu H, Aksu B et al. Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 125(4), 843-848 (2003). (Pubitemid 36457505)
27. Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann. Thorac. Surg. 71(5), 1428-1432 (2001).
28. Byrne JG, Leacche M, Paul S et al. Risk factors and outcomes for vasoplegia syndrome following cardiac transplantation. Eur. J. Cardiothorac. Surg. 25(3), 327-332 (2004). (Pubitemid 38340565)
29. Gomes WJ, Carvalho AC, Palma JH et al. Vasoplegic syndrome after open heart surgery. J. Cardiovasc. Surg. (Torino) 39(5), 619-623 (1998). (Pubitemid 28526021)
30. Gkaliakousi E, Ferro A. Nitric oxide signaling in the regulation of cardiovascular and platelet function. Front. Biosci. 16, 1873-1897 (2011).
31. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 275(1-2), 87-90 (1990). (Pubitemid 20386182)
32. Kilbourn RG, Gross SS, Jubran A et al. NG-methyl-l-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl Acad. Sci. USA 87(9), 3629-3632 (1990).
33. Beasley D, McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J. Exp. Med. 179(1), 71-80 (1994). (Pubitemid 24012972)
34. Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J. Immunother. 34(5), 419-427 (2011).
35. Schmidt HH. NO., CO and .OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett. 307(1), 102-107 (1992).
36. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin. Thorac. Cardiovasc. Surg. 22(2), 140-144 (2010).
37. Bester AM, Harvey BH. Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements. Metab. Brain Dis. 15(4), 275-285 (2000). (Pubitemid 32448877)
38. Lomniczi A, Cebral E, Canteros G, McCann SM, Rettori V. Methylene blue inhibits the increase of inducible nitric oxide synthase activity induced by stress and lipopolysaccharide in the medial basal hypothalamus of rats. Neuroimmunomodulation 8(3), 122-127 (2000). (Pubitemid 32008823)
39. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur. Heart J. 14 (Suppl. I), 22-26 (1993). (Pubitemid 23362589)
40. Ohlstein EH, Wood KS, Ignarro LJ. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch. Biochem. Biophys. 218(1), 187-198 (1982).
41. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. 50(1), 1-5 (1996). (Pubitemid 26250067)
42. Evora PR, Ribeiro PJ, Vicente WV et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev. Bras. Cir. Cardiovasc. 24(3), 279-288 (2009).
43. Leyh RG, Kofidis T, Strber M et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J. Thorac. Cardiovasc. Surg. 125(6), 1426-1431 (2003). (Pubitemid 36759245)
44. Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth. Analg. 103(1), 2-8 (2006). (Pubitemid 44036021)
45. McRobb CM, Holt DW. Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J. Extra. Corpor. Technol. 40(3), 206-214 (2008).
46. Taylor K, Holtby H. Methylene blue revisited: management of hypotension in a pediatric patient with bacterial endocarditis. J. Thorac. Cardiovasc. Surg. 130(2), 566 (2005). (Pubitemid 41074196)
47. Weissgerber AJ. Methylene blue for refractory hypotension: a case report. AANA J. 76(4), 271-274 (2008).
48. Andritsos MJ. Con: methylene blue should not be used routinely for vasoplegia perioperatively. J. Cardiothorac. Vasc. Anesth. 25(4), 739-743 (2011).
49. Riha H, Augoustides JG. Pro: methylene blue as a rescue therapy for vasoplegia after cardiac surgery. J. Cardiothorac. Vasc. Anesth. 25(4), 736-738 (2011).
50. Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 118(1), 195-196 (1999). (Pubitemid 29321017)
51. Pagni S, Austin EH. Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 119(6), 1297-1298 (2000). (Pubitemid 30412634)
52. Kofidis T, Strber M, Wilhelmi M et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J. Thorac. Cardiovasc. Surg. 122(4), 823-824 (2001).
53. Dagenais F, Mathieu P. Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can. J. Cardiol. 19(2), 167-169 (2003). (Pubitemid 36401727)
54. Mora-Ordóñez JM, Sánchez-Llorente F, Galeas-López JL, Hernández Sierra B, Prieto-Palomino MA, Vera-Almazán A. Use of methylene blue in the treatment of vasoplegic syndrome of post-operative heart surgery. Med. Intensiva. 30(6), 293-296 (2006). (Pubitemid 44407914)
55. Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann. Thorac. Surg. 87(2), 640-642 (2009)